What research supports the use of GnRH agonists in the treatment of precocious puberty?

Updated: Nov 30, 2020
  • Author: Paul B Kaplowitz, MD, PhD; Chief Editor: Robert P Hoffman, MD  more...
  • Print

A literature review by Wang et al found that the addition of growth hormone to GnRH agonist therapy resulted in significant height increase, as well as increases in predicted adult height and height standard deviation for bone age, in children with CPP. Efficacy was greater in patients whose initial treatment began prior to age 10 years or whose therapy lasted more than 12 months. [45]  However, the high cost of combined growth hormone–GnRH agonist therapy relative to its modest benefit has generally limited its use to children with a very poor adult height prediction.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!